CN Patent

CN106905294A — 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法

Assigned to Suzhou Best Pharmaceutical Co Ltd · Expires 2017-06-30 · 9y expired

What this patent protects

本发明涉及5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法，具体地为晶型A和晶型C。本发明提供的晶型稳定性良好、溶解度更高、引湿性较低，对未来该药物的优化和开发具有重要价值。

USPTO Abstract

本发明涉及5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法，具体地为晶型A和晶型C。本发明提供的晶型稳定性良好、溶解度更高、引湿性较低，对未来该药物的优化和开发具有重要价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN106905294A
Jurisdiction
CN
Classification
—
Expires
2017-06-30
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Best Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.